Launch of Generic Lialda® Delayed-Release Tablets Expands Mylan's Gastroenterology Product Offering
U.S. sales for Mesalamine Delayed-Release Tablets USP, 1.2 g, were approximately
Currently, Mylan has 168 ANDAs pending
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend. We market our products in more than 165 countries and territories. We are one of the world's largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at Mylan.com. We routinely post information that may be important to investors on our website at investor.mylan.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/launch-of-generic-lialda-delayed-release-tablets-expands-mylans-gastroenterology-product-offering-300767416.html
Christine Waller (Media), 724.514.1968; Melissa Trombetta (Investors), 724.514.1813